📰 Alkermes News
Page 27 - Alkermes News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Alkermes. Real-time updates on events, politics, business and more.
July 24, 2023
/PRNewswire/ -- DelveInsights Cutaneous Melanoma Market Insights report includes a comprehensive understanding of current treatment practices including the...
July 21, 2023
Children and adults with ADHD show greater improvement in symptoms with viloxazine extended release compared with treatment with atomoxetine, new research suggests.
July 19, 2023
Alkermes Celebrates Pride Month
July 19, 2023
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, July 26, 2023 to...
July 14, 2023
Cantor Fitzgerald reiterated their overweight rating on shares of Alkermes (NASDAQ:ALKS – Free Report) in a research note released on Monday morning, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Alkermes’ FY2023 earnings at ($0.56) EPS and FY2024 earnings at $0.58 EPS. Several other equities research analysts have also issued reports on the stock. StockNews.com […]
July 11, 2023
In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Alkermes (ALKS – Research Report), with a price t...
July 11, 2023
Toni K. Choueiri, MD, highlights findings from the CONTACT-03 trial and their clinical significance, as well as the need for continued investigation of PD-1 inhibitor rechallenge despite the negative trial results with cabozantinib and atezolizumab.
July 10, 2023
Shares of Alkermes plc (NASDAQ:ALKS – Free Report) have received an average rating of “Hold” from the five analysts that are covering the company, MarketBeat reports. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1-year price target among brokers that have […]
July 7, 2023
Alkermes plc (NASDAQ:ALKS – Free Report) – Equities researchers at Zacks Research upped their Q2 2024 earnings estimates for Alkermes in a research report issued on Tuesday, July 4th. Zacks Research analyst A. Chakraborty now expects that the company will post earnings per share of $0.62 for the quarter, up from their prior estimate of […]
July 6, 2023
BioNTech SE and the UK government have jointly agreed to provide up to 10,000 patients with personalised cancer immunotherapies by 2030. Signing of this agreement builds on a memorandum of...